Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.
about
Active idiotypic vaccination versus control immunotherapy for follicular lymphomaPleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis.Recognition of antigen-specific B-cell receptors from chronic lymphocytic leukemia patients by synthetic antigen surrogates.Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulinsSelf-antigen recognition by follicular lymphoma B-cell receptors.Clinical evaluation of therapeutic cancer vaccines.Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.Personalized cancer vaccines.Idiotype vaccine strategies for treatment of follicular lymphoma.Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.Idiotype vaccines for lymphoma therapy.Cancer vaccine adjuvants--recent clinical progress and future perspectives.Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma.Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells.Immunotherapy for B-cell lymphoma: current status and prospective advancesPhage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma.Remodeling of the epitope repertoire of a candidate idiotype vaccine by targeting to lysosomal degradation in dendritic cells
P2860
Q33691505-69F257CE-98D5-4E49-A571-CFEE23281CDEQ33703008-81C68BEC-F6E1-4743-A233-886CD6AA8ECDQ35482083-34CF1FD8-2F02-46E3-BCDC-1F03A705DB99Q36386109-681484C7-52C9-4199-9645-CED07ABE0BBFQ36410149-1553983D-8085-47E9-9D78-DEBC321A0BF1Q37505369-08D1FA18-88A9-418C-9B8D-0993A6877A91Q37505384-08CFDC02-4970-4537-97A3-A306E802E405Q37803417-24846556-874C-43DE-8D25-08A130D68A71Q37822740-2473C59A-1F54-4332-B1C6-08C122F609E2Q37863518-AD46292B-82D3-4AD4-BBDA-5B817E3411BFQ37892587-33FE4935-1F43-4A63-9F22-9F0FA022259CQ38260496-92123879-A15A-4BB6-869F-98CBF6ED16F0Q40302619-B2FEB9BE-F141-45B8-8A72-44C0CAEC997EQ41648531-904E5C08-83C4-4BCC-B19F-0F38B546E77DQ41831989-2DCF97E7-1AEE-44AC-AE9A-4E9AD08888B4Q42215347-558A68BE-15EF-4D5E-82E8-B6822A53C921Q57056029-7E7F5FD9-73D5-46CB-929C-D02536478D4F
P2860
Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Tumor-specific recombinant idi ...... llicular non-Hodgkin lymphoma.
@ast
Tumor-specific recombinant idi ...... llicular non-Hodgkin lymphoma.
@en
Tumor-specific recombinant idi ...... llicular non-Hodgkin lymphoma.
@nl
type
label
Tumor-specific recombinant idi ...... llicular non-Hodgkin lymphoma.
@ast
Tumor-specific recombinant idi ...... llicular non-Hodgkin lymphoma.
@en
Tumor-specific recombinant idi ...... llicular non-Hodgkin lymphoma.
@nl
prefLabel
Tumor-specific recombinant idi ...... llicular non-Hodgkin lymphoma.
@ast
Tumor-specific recombinant idi ...... llicular non-Hodgkin lymphoma.
@en
Tumor-specific recombinant idi ...... llicular non-Hodgkin lymphoma.
@nl
P2093
P2860
P1433
P1476
Tumor-specific recombinant idi ...... llicular non-Hodgkin lymphoma.
@en
P2093
Dan W Denney
Debra K Czerwinski
Diane Ingolia
John M Timmerman
Martha Mayo
Ronald Levy
Wen-Kai Weng
P2860
P356
10.1080/10428190802563355
P50
P577
2009-01-01T00:00:00Z